Biogen (BIIB) director Lloyd Minor sells 1,186 shares under 10b5-1 plan

Rhea-AI Filing Summary

Biogen Inc. director Lloyd Minor reported selling a total of 1,186 shares of Biogen common stock in two open-market or private transactions. On 3 August 2026 he sold 593 shares at $203.34 per share, and on 4 August 2026 he sold 593 shares at $200.96 per share.

The trades involve non-derivative common stock held directly and are affirmed as having been executed under a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 1,186 shares

Net Sell 2 txns

Insider Minor Lloyd

Role Director

Sold 1,186 shs ($240K)

Type	Security	Shares	Price	Value
Sale	Common Stock	593	$200.96	$119K
Sale	Common Stock	593	$203.34	$121K

Holdings After Transaction: Common Stock — 2,689 shares (Direct)

Key Figures

Total shares sold: 1,186 shares Shares sold 3 Aug 2026: 593 shares Price on 3 Aug 2026: $203.34 per share +3 more

6 metrics

Total shares sold 1,186 shares Aggregate shares sold across two reported transactions

Shares sold 3 Aug 2026 593 shares Non-derivative common stock sale on 2026-08-03

Price on 3 Aug 2026 $203.34 per share Sale price for 593 common shares on 2026-08-03

Shares sold 4 Aug 2026 593 shares Non-derivative common stock sale on 2026-08-04

Price on 4 Aug 2026 $200.96 per share Sale price for 593 common shares on 2026-08-04

Number of sale transactions 2 Count of reported sale transactions in this Form 4

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, non-derivative

3 terms

Rule 10b5-1 trading plan regulatory

"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction financial

"Transaction code S: Sale in open market or private transaction."

non-derivative financial

"Each transaction is classified as a non-derivative common stock transaction."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/05/2026 - 04:03 PM Accepted by SEC EDGAR 08/05/2026 - 04:03 PM Learn about SEC filing dates

FAQ

What insider transaction did Biogen (BIIB) director Lloyd Minor report?

Lloyd Minor reported selling 1,186 shares of Biogen common stock in two transactions. The sales were of non-derivative common stock held directly and were executed under a Rule 10b5-1 trading plan for pre-arranged trades.

On what dates did Lloyd Minor sell Biogen (BIIB) shares and at what prices?

Lloyd Minor sold Biogen shares on 3 August 2026 and 4 August 2026. He sold 593 shares at $203.34 per share on 3 August and 593 shares at $200.96 per share on 4 August in open-market or private transactions.

How many Biogen (BIIB) shares in total did Lloyd Minor sell in this Form 4?

The Form 4 reports that Lloyd Minor sold a total of 1,186 shares of Biogen common stock. This total reflects two equal-sized transactions of 593 shares each, both classified as sales in open-market or private transactions.

Were Lloyd Minor’s Biogen (BIIB) stock sales made under a Rule 10b5-1 plan?

Yes. The report affirms that the transactions were executed under a Rule 10b5-1 trading plan. This indicates the sales followed a pre-established trading arrangement rather than discretionary timing decisions made on the transaction dates.

What type of security did Lloyd Minor sell in Biogen (BIIB)?

Lloyd Minor sold Biogen common stock, classified as a non-derivative security. Both reported transactions involve sales of common shares directly owned, rather than options or other derivative instruments, in open-market or private transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Minor Lloyd

(Last) (First) (Middle)

225 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S		593	D	$203.34	3,282	D
Common Stock	08/04/2026		S		593	D	$200.96	2,689	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Wendell Taylor, attorney-in-fact for Dr. Minor	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)